Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

Kidney International

Volumn 81, Issue 8, 2012, Pages 727-732

  MacDougall, Iain C ^a   Roger, Simon D ^b   De Francisco, Angel ^c   Goldsmith, David J A ^d   Schellekens, Huub ^e   Ebbers, Hans ^e   Jelkmann, Wolfgang ^f   London, Gérard ^g   Casadevall, Nicole ^h   Hörl, Walter H ⁱ   Kemeny, David M ^j   Pollock, Carol ^k  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GOSFORD HOSPITAL   (Australia)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d GUY S HOSPITAL   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF LÜBECK   (Germany)

^g Centre Hospitalier Manhes   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

anemia; chronic kidney disease; clinical nephrology; pure red cell aplasia

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; PEGINESATIDE; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; TUNGSTEN;

ANEMIA; ANTIBODY DETECTION; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICELLIZATION; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PURE RED CELL ANEMIA; RADIOIMMUNOPRECIPITATION; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; TREATMENT DURATION;

EID: 84859424243     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.500     Document Type: Short Survey

References (48)

1. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48: 1754-1762.
2. Casadevall N, Nataf J, Viron B. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475. (Pubitemid 34441737)
3. Pollock C, Johnson DW, Hörl WH et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199.
4. Macdougall IC, Rossert J, Casadevall N et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361: 1848-1855 (Supplementary Appendix available from: http://www.nejm.org/doi/ suppl/10.1056/NEJMoa074037/suppl-file/nejm-macdougall-1848sa1.pdf accessed 3 December 2010).
5. Shimizu H, Saitoh T, Ota F et al. Pure red cell aplasia induced by only intravenous administration of recombinant human erythropoietin. Acta Haematol 2011; 126: 114-118.
6. Chailimpamontree W, Gojaseni P, Pajareya T et al. Pure red cell aplasia due to continuous erythropoietin receptor activator (CERA): a case report. Poster presentation at the XLVIII ERA-EDTA Congress, Prague, Czech Republic, June 2011.
7. Haag-Weber M, Eckardt K-U, Hörl WH et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin alfa (HX575) in non-dialysis patients with renal anaemia: a multi-centre, randomised, double-blind study. Clin Nephrol 2012; 77: 8-17.
8. Seidl A, Richter M, Fischer R et al. Tungsten-mediated unfolding and aggregation of epoetin alfa in prefilled syringes as root cause for the occurrence of neutralising antibodies in an investigational clinical trial of subcutaneous administration. Pharm Res 2012: doi:10.1007/s11095-011-0621-4.
9. Van Beers MM, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 2010; 30: 767-775.
10. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 2006; 3: 123-130. (Pubitemid 44266961)
11. Casadevall N, Dupuy E, Molho-Sabatier P et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334: 630-633. (Pubitemid 26072120)
12. Ryan MH, Heavner GA, Brigham-Burke M et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 2006; 6: 647-655.
13. Hermeling S, Schellekens H, Crommelin DJ et al. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903-1907. (Pubitemid 38005518)
14. Sauerborn M, Brinks V, Jiskoot W et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010; 31: 53-59.
15. Brinks V, Hawe A, Basmeleh AH et al. Quality of original and biosimilar epoetin products. Pharm Res 2011; 28: 386-393.
16. Fotiou F, Aravind S, Wang PP et al. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 2009; 31: 336-346.
17. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008; 74: 1617-1622.
18. Praditpornsilpa K, Tiranathagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
19. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. European Medicines Agency: London, UK, 2006. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003953.pdf (accessed 31 August 2011).
20. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. European Medicines Agency: London, UK, 2006. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003920.pdf (accessed 31 August 2011).
21. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency: London, UK, 2007. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003946.pdf (accessed 31 August 2011).
22. Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Erythropoietins (Revision). Euopean Medicines Agency: London, UK, 2010. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2010/04/WC500089474.pdf (accessed 31 August 2011).
23. Weise M, Bielsky M-C, De Smet L et al. Biosimilars - why terminology matters. Nat Biotech 2011; 29: 690-693.
24. Casadevall N, Thorpe R, Schellekens H. Biosimilars need comparative clinical data. Kidney Int 2011; 80: 553.
25. Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009; 15: 34-40.
26. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004; 3: 43-49.
27. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25: 954-962. (Pubitemid 40917928)
28. Jiang Y, Nashed-Samuel Y, Li C et al. Tungsten-induced protein aggregation: solution behavior. J Pharm Sci 2009; 98: 4765-4770.
29. Bee JS, Nelson SA, Freund E et al. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 2009; 98: 3290-3301.
30. Liu W, Swift R, Torraca G et al. Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes. PDA J Pharm Sci Tech 2010; 64: 11-19.
31. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001; 90: 1-11. (Pubitemid 32050471)
32. Larocca AP, Leung SC, Marcus SG et al. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta. J Interferon Res 1989; 9(Suppl 1): S51-S60.
33. Jahn EM, Schneider CK. How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations. Nat Biotechnol 2009; 25: 280-286.
34. Weber G, Gross J, Kromminga A et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenges with different epoetins. J Am Soc Nephrol 2002; 13: 2381-2383. (Pubitemid 34925249)
35. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia 'epidemic' -mystery completely revealed? Perit Dial Int 2007; 27(Suppl 2): S303-S307. (Pubitemid 350047719)
36. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1385-1387.
37. Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-2734. (Pubitemid 41103380)
38. Luraschi A, Montanara S, Fedeli P et al. Pure red cell aplasia in patient affected by myelodysplastic syndrome treated with R-Epo. Recenti Prog Med 2008; 99: 255-257. (Pubitemid 351731684)
39. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21(Suppl 5): v9-v12. (Pubitemid 44391026)
40. Praditpornsilpa K, Buronasot S, Bhokaisuwan N et al. Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation. Nephrol Dial Transplant 2005; 20: 626-630. (Pubitemid 40378436)
41. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W et al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQBI*0309. Nephrol Dial Transplant 2009; 24: 1545-1549.
42. Fijal B, Ricci D, Vercammen E et al. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics 2008; 9: 157-167. (Pubitemid 351566940)
43. Delluc S, Ravot G, Maillere B. Quantification of the pre-existing CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010; 116: 4542-4545.
44. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005; 20(Suppl 4): iv23-iv26. (Pubitemid 40711821)
45. Verhelst D, Rossert J, Casadevall N et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-1771. (Pubitemid 38698380)
46. Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF caused by anti-erythropoietin antibodies after kidney transplantation. Am J Kidney Dis 2003; 41: 692-695. (Pubitemid 36278389)
47. Andrade J, Taylor PA, Love JM et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 2005; 20: 2548-2551. (Pubitemid 41548887)
48. Macdougall IC, Roche A, Rossert J et al. Re-challenging a patient who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant 2004; 19: 2901-2905. (Pubitemid 39480992)